In addition, patients with de novo CD5+ DLBCL tended to have a worse prognosis than CD5‐negative cases, which is in agreement with Yamaguchi et al46 In our previous report on primary gastric DLBCL (gDLBCL), miPD‐L1‐negativity (<20%) and CD5 positivity were not confirmed to have poorer outcomes in contrast to iDLBCL, whereas EBV harboring on tumor cells was an independent adverse factor in both the gDLBCL and iDLBCL series.14 Notably, none of the gDLBCL cases examined in our series expressed PD‐L1 on tumor cells. The gene discussed is CD5; the disease is diffuse large B-cell lymphoma.